Basic & Clinical Medicine ›› 2019, Vol. 39 ›› Issue (2): 277-280.

Previous Articles     Next Articles

Research progress on gene mutations and targeted therapy of type II endometrial carcinoma

Hai-Fang WUXiang-Yu MENG2,Heng-Yi Xu2, 2   

  • Received:2017-11-23 Revised:2018-01-24 Online:2019-02-05 Published:2019-01-16

Abstract: Endometrial carcinoma (EC) is one of the most commen gynecological cancer, Its subtype non-estrogen-dependent endometrial carcinoma (type II) is usually associated with gene abnormalities such as P53 gene mutation and HER-2 overexpression. Molecular targeted therapy may improve the therapeutic effect and prognosis of type II endometrial carcinoma.

Key words: Type II endometrial carcinoma, Gene mutation, Targeted therapy